P027 Vedolizumab induced extensive purpuric dermatitis in patient with severe Crohn's disease: A case report

作者
Glenn K. Harvin,Naseer Maliha
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:114 (1): S7-S8 被引量:1
标识
DOI:10.14309/01.ajg.0000578180.81632.bb
摘要

INTRODUCTION: Crohn's disease is an idiopathic and inflammatory disease of the intestinal tract associated with significant morbidity and mortality. Currently available treatment options for Crohn's disease includes anti-inflammatory drugs, immunosuppressant, biologic agents, antibiotics, and drugs for symptomatic relief. However, variety of dermatological side effects has been reported in literature associated with these modalities. Vedolizumab is approved to induce and maintain remission in moderate to severe Crohn's disease with relatively low side effect profile. Here we present the first reported case of extensive purpuric dermatitis associated with Vedolizumab. CASE: A 56-year-old African American male with history of severe Crohn's disease presented with the complains of extensive bilateral lower extremity rash. Crohn's disease was diagnosed in 2012 involving duodenum and terminal ileum. He was previously treated but failed to respond to 6 mercaptopurine (6-MP), mesalamine, steroids and infliximab infusions. Vedolizumab was started after he failed infliximab. According to patient he noticed rash first time 5 days after first dose of Vedolizumab. He received total of 4 biweekly doses of Vedolizumab before presentation to clinic with rash. Rash was pruritic in nature and started on ankle and progressively got worsened involving legs and thighs. Patient denied history of fever and chills. Review of system was negative. On physical examination well-demarcated, brownish pigmentation over the lower extremities were noticed. He denied use of any other newly prescribed or over the counter medications. Patient underwent a formal dermatologic evaluation. Shave biopsy was done that showed irritated hyper and parakeratotic skin with spongiosis, extravasated red blood cells and inflammatory infiltrate comprising of lymphocytes, histiocytes, neutrophils and eosinophils findings consistent with drug induced purpuric dermatitis. Patient was started on topical triamcinolone. He reported slight improvement in his rash one month after Vedolizumab infusion was discontinue. DISCUSSION: Vedolizumab is a humanized monoclonal antibody that selectively inhibits the binding of α4β7 integrin to intestinal mucosal cell adhesion molecule (MAdCAM-1) and has no effect on α4β1 integrin adhesion on the vascular cell adhesion molecule 1 (VCAM-1). As a result, cutaneous migration of lymphocytes including by VCAM-1 is unaffected. Cutaneous complications of Vedolizumab including rash and hypersensitivity reaction are reported in <1% of patient. Till date only one report of Vedolizumab associated paradoxical psoriasis has been reported. This is the first reported case of extensive purpuric dermatitis (PD) associated with Vedolizumab. Exact etiology of PD is unknown but cell-mediated immunity might play a role. This inflammatory infiltrate leads to vascular fragility and subsequent leakage of erythrocytes. Management of drug induced PD involves discontinuation of offending medication. Topical corticosteroid therapy may be of some help, especially for pruritus, but prolonged use should be avoided. CONCLUSION: Though dermatological complications associated with Vedolizumab are rare but can be potentially debilitating for our patients. Prompt identification and discontinuation of Vedolizumab is critical in preventing morbidity associated with these side effects.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被elang采纳,获得10
1秒前
1秒前
dougsong发布了新的文献求助10
1秒前
1秒前
小柒完成签到 ,获得积分10
1秒前
Zzz完成签到,获得积分10
1秒前
未闻明日之花完成签到,获得积分10
2秒前
研友_GZ3zRn完成签到 ,获得积分0
3秒前
淡然以筠完成签到 ,获得积分10
3秒前
我爱吃糯米团子完成签到,获得积分10
3秒前
子木完成签到 ,获得积分10
3秒前
rf完成签到,获得积分10
3秒前
材料化学左亚坤完成签到,获得积分10
3秒前
鳗鱼铸海完成签到 ,获得积分10
4秒前
完美的映秋完成签到,获得积分10
4秒前
4秒前
5秒前
蜂蜜柚子完成签到,获得积分10
5秒前
打打的应助被lx采纳,获得10
5秒前
开朗紫完成签到,获得积分10
5秒前
Gabi完成签到,获得积分10
5秒前
5秒前
5秒前
科研小能手完成签到,获得积分0
6秒前
Rjy完成签到,获得积分10
6秒前
君看一叶舟完成签到 ,获得积分10
7秒前
7秒前
小范完成签到 ,获得积分10
7秒前
organicdog完成签到,获得积分10
8秒前
小黑球发布了新的文献求助10
8秒前
8秒前
zhuxl完成签到,获得积分10
9秒前
Happy雪晴完成签到,获得积分10
9秒前
10秒前
xiaowang发布了新的文献求助10
10秒前
李亚楠完成签到,获得积分20
10秒前
FRDM完成签到 ,获得积分10
11秒前
Shale完成签到,获得积分10
11秒前
王亮发布了新的文献求助10
11秒前
南荒完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039